Form 4: Gossamer Bio EVP Waage Boosts Stake with New Equity Awards

Gossamer Bio's EVP of Technical Operations and Administration, Christian Waage, received significant equity awards, including restricted stock units and stock options, effective January 2, 2026.

Summary

• Christian Waage, EVP, Tech Ops and Admin at Gossamer Bio, Inc. (GOSS), acquired 84,500 shares of Common Stock as a Restricted Stock Unit (RSU) award on January 2, 2026, with a transaction price of $0.
• The RSU award will vest in four equal annual installments, contingent on continuous service to the Issuer on each vesting date.
• Waage also acquired 506,250 Stock Options (Right to Buy) on January 2, 2026, with an exercise price of $2.88 per share.
• 25% of the stock options will vest on January 2, 2027, with the remaining 1/48th vesting on the last day of each subsequent one-month period, also subject to continuous service.
• The stock options have an expiration date of January 1, 2036.
• Following these transactions, Waage directly beneficially owns 814,061 shares of Common Stock and 506,250 derivative securities (stock options).
• Indirect beneficial ownership includes 45,892 shares via a family trust and 22,222 shares via a trust FBO son.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates an executive's increased stake and long-term alignment with the company's performance through equity awards, which is generally viewed favorably by investors.

Positives

• The grant of significant equity awards (84,500 RSUs and 506,250 stock options) aligns the executive's financial interests with those of shareholders, incentivizing long-term company performance.
• The stock options have an exercise price of $2.88, indicating a potential for future value creation if the stock price appreciates above this level.

Negatives

• The equity awards are subject to multi-year vesting schedules, meaning the executive does not immediately realize the full value of the grants.
• The value of the awards is contingent on the company's future stock performance and the executive's continuous employment.

Risks

• Vesting Risk: The awards are subject to forfeiture if the reporting person's continuous service to the Issuer ceases before the vesting dates.
• Market Price Risk: The ultimate value realized from the stock options is dependent on the future market price of Gossamer Bio's common stock exceeding the exercise price of $2.88.
• Dilution Risk: The issuance of new shares upon vesting of RSUs and exercise of options could lead to minor dilution for existing shareholders, though this is standard for equity compensation.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the executive to the company's future performance and growth, aligning their incentives with shareholder value creation.

Industry Context

The granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, designed to attract, retain, and incentivize key personnel by linking their compensation to the company's long-term success and stock performance.

Stakeholder Impact

• Shareholders: The equity awards align the executive's interests with shareholders, potentially leading to more focused efforts on increasing shareholder value. However, future share issuance upon vesting/exercise could result in minor dilution.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Vesting of 25% of stock options on January 2, 2027.
• Subsequent monthly vesting of stock options (1/48th of total) after January 2, 2027.
• Annual vesting of restricted stock units over four years, starting from January 2, 2026.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, insider transaction, executive compensation, restricted stock unit, RSU, stock option, equity award, vesting, beneficial ownership